MGC Diagnostics’ Post

DCRI's Jennifer Rymer and Schuyler Jones, along with former DCRI member Sunil Rao, joined their colleagues at #ACC24 this morning for a deep dive into the ACS toolbox, where they examined guidelines, proven and potential therapies, and opportunities to tailor approaches to each patient's unique characteristics and needs. Jones took the opportunity to reinforce GDMT adherence after ACS and noted 30% of patients still don't receive the Big 5 (aspirin, beta blockers, ACE inhibitors, statins, P2Y12 inhibitors). #clinicaltrials #clinicalresearch #hearthealth #heartdisease

Calling All MGC Diagnostics Users! Share Your Testing Tips & Ask Us Anything!** We're always looking for ways to improve your experience with MGC Diagnostics products. Do you have any testing tips or tricks you'd like to share with the community? Maybe you have a question about a specific MGC Diagnostics product and can't find the answer? Let us know in the comments below! We'll be featuring some of the best tips and answering your questions throughout the week. #pulmonaryfunctiontesting #diagnostics #respiratorycare #community #CPET #SportsMedicine

The countdown begins! Are you attending World CB & CDx in London next week? Swing by our booth to discuss the latest companion diagnostics (CDx) innovations. Feel free to message us on LinkedIn to schedule a meeting or learn more. #cdx #companiondiagnostics #personalizedmedicine #worldcdx

On behalf of everyone at ivWatch, LLC, I welcome the opportunity to share some recent remarkable achievements, solidifying our commitment to improving and promoting IV safety around the globe.   This past year has been marked by significant growth, ground-breaking innovation, and partnerships that will fuel our continued expansion in 2024 and beyond.   I am so proud to highlight:   Surpassing Key Metrics: 👉We surpassed 7.7 million hours of patient monitoring, impacting the lives of over 230,000 patients worldwide. 👉Three of the top ten US children's hospitals adopted our technology, demonstrating its impact on the most vulnerable patients. 👉We achieved pristine quality assurance on every order, maintaining the highest standards of manufacturing in our US Virginia facility.   Innovation and Regulatory Progress: 👉We secured our 69th patent for our biosensor technology, further solidifying our intellectual property leadership. 👉We filed for 510(k) clearance with the FDA to detect extravasation events during iron infusions, expanding our potential patient impact. 👉We published two clinical studies in The Journal of Vascular Access, demonstrating the effectiveness of our system in early detection of leaks.   Global Expansion and Recognition: 👉We participated in major conferences, showcasing our innovations and raising awareness about IV safety. 👉We received prestigious awards recognizing our innovation, leadership, and marketing excellence.   Strategic Partnerships and Advocacy: 👉We partnered with leading distributors in key markets, ensuring accessibility to our technology. 👉We secured a significant agreement with Premier, Inc., granting vital access to top children’s hospitals.   This incredible journey would not have been possible without the dedication and passion of our entire team, our supportive partners, and the trust placed in us by healthcare professionals around the world! #ivWatch #HeleStephens #IVsafety #infusionsafety 

Did you know? Almac's IXRS®3 IRT platform supports DTP (Direct-to-Patient) workflow management for Decentralised Clinical Trials (DCTs). For rare disease patients who may face limited trial availability and travel challenges, DCTs and DTP shipments offer an opportunity to participate in research for new treatments and therapies. Visit our website to learn more about our direct-to-patient and supply management capabilities. https://okt.to/ELe9xy #raredisease #clinicaltrials #decentralisedtrials

Do you know about 3 million Americans have glaucoma, which is the second leading cause of blindness worldwide. Glaucoma cannot be cured, but with appropriate action your vision can be preserved. Once you are diagnosed with glaucoma and have started treatment, you may want to join a support group so that you can talk to people who have the same condition and can understand what living with glaucoma means. Other things you may try is to improve the lighting in your house to make it easier for reading and carrying out your usual daily living. Your eye doctor may also prescribe new glasses that magnify your vision without affecting your everyday life. Maintaining a healthy lifestyle is also beneficial in not only general health but also eye health. Finally, rest assured that glaucoma is not the end of world, and with proper support and treatment, you can continue with enjoying your life into the future. At Prove Labs, we have a long history with glaucoma, founded be renown Ophthalmologist Dr Andrew Chang. We are uniquely positioned to be able to support you laboratory needs for your clinical trial. Find out more about how we can support you by visiting www.provelabs.com #glaucomaawarenessmonth #provelabs #biotech #glaucoma #eyehealth

Did you know? Almac's IXRS®3 IRT platform supports DTP (Direct-to-Patient) workflow management for Decentralised Clinical Trials (DCTs). For rare disease patients who may face limited trial availability and travel challenges, DCTs and DTP shipments offer an opportunity to participate in research for new treatments and therapies. Visit our website to learn more about our direct-to-patient and supply management capabilities. https://okt.to/eVFq7C #raredisease #clinicaltrials #decentralisedtrials

5 Things to Know - Thing 1) Shockwave Medical $SWAV Being Acquired by Johnson & Johnson $JNJ: DKI Takeaway: DKI recommended Shockwave Medical $SWAV to subscribers in December at $190. Our positive thesis was based on an expected takeover for more than $300 per share. Boston Scientific $BSX approached Shockwave last year. They could return to bid again, but given that the $JNJ talks have been public for more than a week and that there’s now a breakup fee, it’s possible but unlikely they re-enter the situation. DKI subscribers made more than 70% in under four months. This is the second DKI portfolio company to be acquired following Houghton Mifflin which was bought for more than 4x DKI’s initial purchase price. If that’s of interest to you, you’re welcome to subscribe. Otherwise, we’ll be happy to keep informing you after the fact. https://lnkd.in/gV5RdcGT

Eid al-Fitr, also known as the Festival of Breaking Fast, is a significant celebration in Islam. It marks the end of Ramadan, the holy month of fasting. Here are some key points about Eid al-Fitr: 1. Timing: Eid al-Fitr occurs during the first three days of Shawwāl, which is the 10th month of the Islamic lunar calendar. Due to the lunar calendar, it can fall in any season of the year. 2. bservance: On the first day of Eid al-Fitr, Muslims perform a communal prayer (ṣalāt) at daybreak. This prayer is a central part of the celebration. 3. Traditions and Customs: - Receptions and Visits: It’s a time for official receptions and private visits. Friends greet one another, exchange gifts, and wear new clothes. - Charity: Muslims engage in acts of charity and kindness, helping those in need. - Family Bonding: Families come together, share meals, and visit the graves of relatives. 4. Joyous Celebration: Eid al-Fitr is a joyous occasion, filled with communal prayers, parties, special foods, and festive clothing. It’s a time to express gratitude and celebrate the end of Ramadan.

Read highlights from #esmo2023 on Medthority: "According to Rönningås, pain experience in men with mCRPC differs between those using analgesics from those who do not. Pain management was not effective for more than half of the participants with mCRPC, even for those using analgesics." #esmo #pain #painrelief #painmanagement #chronicpain #analgesics #opioids #endoflifecare #palliativecare